15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 20 firms covering Biomarin Pharmaceutical Inc, 15 rate it Buy or better, 5 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $50.00 to $120.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $84.41 sits 36% above the current $62.08. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 14 to 15 over recent months. On the fundamentals, the Street sees revenue growth near 20% this year and 14% next, consensus EPS building from about $1.49 next quarter toward $6.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS20 ratings
Moderate Buy
Strong Buy00%
Buy1575%
Hold525%
Sell00%
Strong Sell00%
Based on 20 analysts giving stock ratings to Biomarin Pharmaceutical Inc.
As of Jul, 15 of 20 firms rate BMRN a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BMRN EPS & revenue forecast
EPS · NEXT QUARTER
$1.49
Range $1.38 – $1.71 · 15 analysts · +1142% YoY
Next period, 15 analysts expect Biomarin Pharmaceutical Inc to earn $1.49 a share (range $1.38 – $1.71), versus $0.12 a year earlier. Full-year consensus is $4.93, growing to $6.39 the year after.
REVENUE · NEXT QUARTER
$1.0B
Range $991.5M – $1.1B · 15 analysts · +35% YoY
Revenue is expected to reach $1.0B (range $991.5M – $1.1B), +35.0% year-over-year. Full-year consensus is $3.9B, rising to $4.4B next year.
Top analysts covering Biomarin Pharmaceutical Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BMRN.
#1
Jessica Fye
JP Morgan · Rank #64
Buy
No targeton BMRN
Overall win rate
52%
+ Follow
#2
Jason Gerberry
B of A Securities · Rank #136
Buy
$80.00+28.9% to target
Overall win rate
46%
+ Follow
#3
Mitchell Kapoor
HC Wainwright & Co. · Rank #165
Hold
$50.00-19.5% to target
Overall win rate
34%
+ Follow
#4
Matthew Harrison
Morgan Stanley · Rank #243
Buy
$119.00+91.7% to target
Overall win rate
44%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #254
Buy
$95.00+53.0% to target
Overall win rate
37%
+ Follow
BMRN stock forecast FAQ
What is BMRN's average 12-month price target?+
The 17 analysts with a live target average $84.41 for Biomarin Pharmaceutical Inc over the next 12 months, ranging from a $120.00 high to a $50.00 low.
Is BMRN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 20 analyst ratings, 15 are Buy or Strong Buy, 5 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BMRN?+
The Street-high target is $120.00 (Evercore ISI Group), and the Street-low is $50.00 (HC Wainwright & Co.). The average of all 17 active targets is $84.41.
How many Wall Street analysts cover BMRN?+
20 analysts have an active rating on Biomarin Pharmaceutical Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering BMRN?+
Among analysts who currently cover BMRN, Jessica Fye of JP Morgan has the strongest overall Quantellect track record (Rank #64). Their current call is Buy.
What is Biomarin Pharmaceutical Inc's projected EPS for next quarter?+
The consensus estimate is $1.49 per share (range $1.38 – $1.71) across 15 analysts. Full-year EPS is projected at $4.93, rising to $6.39 the following year.
How much revenue is Biomarin Pharmaceutical Inc expected to report next quarter?+
Consensus revenue is $1.0B (range $991.5M – $1.1B). Full-year revenue is projected at $3.9B, growing to $4.4B next year.
Have analysts been upgrading or downgrading BMRN lately?+
As of Jul, 15 of 20 firms rate BMRN a Buy (5 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BMRN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
